PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 05: Articles 2001-2500 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. Oral contraceptive regimen that doubles the number of hormonally active pills per cycle reduces bleeding.
  2. Contraception counts: Alabama.
  3. Contraception counts: Alaska.
  4. Contraception counts: Arkansas.
  5. Contraception counts: California.
  6. Contraception counts: Colorado.
  7. Contraception counts: Connecticut.
  8. Contraception counts: Delaware.
  9. Contraception counts: District of Columbia.
  10. Contraception counts: Florida.
  11. Contraception counts: Georgia.
  12. Contraception counts: Hawaii.
  13. Contraception counts: Idaho.
  14. Contraception counts: Illinois.
  15. Contraception counts: Indiana.
  16. Contraception counts: Iowa.
  17. Contraception counts: Kansas.
  18. Contraception counts: Kentucky.
  19. Contraception counts: Louisiana.
  20. Contraception counts: Maine.
  21. Contraception counts: Maryland.
  22. Contraception counts: Massachusetts.
  23. Contraception counts: Michigan.
  24. Contraception counts: Minnesota.
  25. Contraception counts: Mississippi.
  26. Contraception counts: Missouri.
  27. Contraception counts: Montana.
  28. Contraception counts: Nebraska.
  29. Contraception counts: Nevada.
  30. Contraception counts: New Hampshire.
  31. Contraception counts: New Jersey.
  32. Contraception counts: New Mexico.
  33. Contraception counts: New York.
  34. Contraception counts: North Carolina.
  35. Contraception counts: North Dakota.
  36. Contraception counts: Ohio.
  37. Contraception counts: Oklahoma.
  38. Contraception counts: Oregon.
  39. Contraception counts: Pennsylvania.
  40. Contraception counts: Rhode Island.
  41. Contraception counts: South Carolina.
  42. Contraception counts: South Dakota.
  43. Contraception counts: Tennessee.
  44. Contraception counts: Texas.
  45. Contraception counts: Utah.
  46. Contraception counts: Vermont.
  47. Contraception counts: Virginia.
  48. Contraception counts: Washington.
  49. Contraception counts: West Virginia.
  50. Contraception counts: Wisconsin.
  51. Contraception counts: Wyoming.
  52. Family planning and reproductive health in the context of the HIV / AIDS in South Africa: issues affecting family planning service delivery.
  53. Analysis of family planning / HIV / AIDS integration activities within the USAID Population, Health and Nutrition Center. Results of a survey conducted by Advance Africa and the CATALYST Consortium.
  54. Family-planning office won't compromise on contraceptives.
  55. Researcher to refine contraceptive implant.
  56. China protects women's choice on contraception.
  57. China shifts family planning focus to reproductive services.
  58. Family planning logistics: strengthening the supply chain./Logistique de la planification familiale : renforcer la filiere de l'approvisionnement./Logistica de la planificacion familiar: como fortalecer la cadena de suministros.
  59. Contraception endangered by legal challenge to emergency pill.
  60. Court rules that emergency contraception is lawful.
  61. Depo-Provera contraceptive may increase risk of cardiovascular disease.
  62. Dutch GPs warned against new contraceptive pill.
  63. New study adds to evidence that taking oral contraception does not increase risk of breast cancer.
  64. Oral contraceptives, venous thromboembolism, and the courts. There has to be a better way of resolving claims about adverse effects [editorial]
  65. Breast-feeding and contraception in Peru. [Lactancia materna y anticoncepción en Perú.]
  66. Increasing contraceptive acceptance through empowerment of female community health volunteers in rural Nepal.
  67. Male contraception.
  68. Male contraception. [La contraception masculine.]
  69. Maternal sepsis and intrauterine fetal death resulting from Candida tropicalis chorioamnionitis in a woman with a retained intrauterine contraceptive device.
  70. MEASURE DHS+ interviewer's manual for use with model "A" questionnaire for high contraceptive prevalence countries.
  71. MEASURE DHS+ interviewer's manual for use with model "B" questionnaire for low contraceptive prevalence countries.
  72. Methods of local contraception. [Les méthodes de contraception locale.]
  73. Mifepristone in combination with misoprostol vs. low dose mifepristone alone in emergency contraception: a multi-center double-blind randomized clinical trial.
  74. Mifepristone, methotrexate and emergency contraception.
  75. Mixed reaction to proposed dual standards for birth control.
  76. MRCOG Part II model essay answer. Describe the contraceptive options and their advantages and disadvantages, for a 20-year-old nulliparous woman taking the combined oral contraceptive, who develops severe headaches during the pill-free week.
  77. A multivariate decomposition of covariates of contraceptive use in Uttar Pradesh.
  78. A narrow view of family planning [letter]
  79. National Family Planning and Reproductive Health Survey (2001)
  80. National Family Planning and Reproductive Health Survey (2001)
  81. National population and family planning program by the year 2005.
  82. Natural contraception using the Billings ovulation method.
  83. New developments in contraception.
  84. 20. Oral contraceptives, hormone replacement therapy and breast cancer.
  85. Abnormal uterine bleeding associated with hormonal contraception.
  86. Abstinence promotion and teen family planning: the misguided drive for equal funding.
  87. Adolescent emergency contraception: attitudes and practices of certified nurse-midwives.
  88. Adolescents and emergency contraception.
  89. Alterations in gonadotropin levels following oral and vaginal administration of the Yuzpe regimen and Plan B for emergency contraception.
  90. Antenatal utilization, family planning and fertility preferences in Tari.
  91. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice.
  92. Architecture and power: a family planning clinic as a case study.
  93. As menopause approaches, needs change. But contraception is still important for sexually active older women.
  94. Attitudes among non-acceptors of family planning methods: men's perspective.
  95. Attitudes towards contraceptive pill use in two different populations in Thrace, Greece.
  96. Bleeding patterns with hormonal contraceptives and IUDs.
  97. Bone mineral density and hormonal contraception. [Densité minérale osseuse et contraception hormonale.]
  98. Breastfeeding, amenorrhea and contraceptive practice among postpartum women in Zibo, China.
  99. Broadening commercial sector participation in reproductive health. The role of public sector prices on markets for oral contraceptives. [Elargissement de la participation du secteur commercial à la santé reproductive. Rôle des prix du secteur privé sur le marché des contraceptifs oraux.]
  100. Bush holds funds for U.N. family planning.
  101. CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception.
  102. A call to action. Acculturation level and family-planning patterns of Hispanic immigrant women.
  103. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? A discussion based on recent recommendations from the European agency for evaluation of medicinal products regarding third generation oral contraceptive pills.
  104. Can Vietnam's family planning collaborators improve grassroots reproductive health services? Results of an assessment in two communes.
  105. CARE International's community-based distribution program in eastern Ethiopia increases contraceptive use.
  106. Cervical cap versus diaphragm for contraception.
  107. Changed routines in connection with first prescription of oral contraceptives. Lower risk of venous thromboembolism with levonorgestrel preparations. [Ändrade rutiner vid nyförskrivning av p-piller. Preparat med levonorgestrel ger lägst risk för venös tromboembolism.]
  108. China enacts new family planning and population law.
  109. China Family Planning Association releases new HIV / AIDS education materials.
  110. Choice of contraception and gyneco-mammary pathologies. [Choix d'une contraception et pathologies gynéco-mammaires.]
  111. Cholinesterase activity in female greenhouse workers: influence of work practices and use of oral contraceptives.
  112. The church and family planning. Bush removes funding for UNFPA.
  113. Clinical experience with Norplant subdermal implant system as long-term contraception during adolescence.
  114. A clinical update on transdermal contraception. Correct use.
  115. A clinical update on transdermal contraception. Efficacy.
  116. A clinical update on transdermal contraception. Frequently asked questions about transdermal contraception.
  117. A clinical update on transdermal contraception. Pharmacology, mechanism of action, and dosing.
  118. A clinical update on transdermal contraception. Safety and tolerability.
  119. A clinical update on transdermal contraception. Selecting candidates and counseling users.
  120. A clinical update on transdermal contraception. The need for new contraceptive options.
  121. Coitus-dependent and coitus-independent contraceptive methods in women and men.
  122. Combined estrogen-progestin hormonal contraception. [La contraception hormonale estroprogestative.]
  123. Commentary: Judicial review of the pharmacy provision of emergency contraception in the UK.
  124. Communicating with men to promote family planning: lessons learned and suggestions for programming. [Comunicación con los hombres para promover la planificación familiar: lecciones aprendidas y sugerencias para la programación.]
  125. A comparison of consensus and nonconsensus approaches to modeling contraceptive choice behavior.
  126. Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism.
  127. A conceptual framework to evaluate government family planning programme efforts in Nepal.
  128. Condoms and contraception.
  129. A consequence of success: the issue of contraceptive security in Bangladesh. A discussion paper.
  130. Contests on radio and TV programs on population and family planning.
  131. Continuation and compliance of contraceptive use.
  132. Continuous oral contraceptive use.
  133. Contraception after forty. [La contraception à partir de 40 ans.]
  134. Contraception and collagenosis. [Contraception et connectivités.]
  135. Contraception and induced abortion: legislative measures creating exceptions to parental consent in France. [Contraception et interruption volontaire de grossesse: mesures legislatives derogatoires au consentement des parents en France.]
  136. Contraception and society.
  137. Contraception during a person's forties. [Contraception a la quarantaine.]
  138. Contraception in adolescent girls. [La contraception chez l'adolescente.]
  139. Contraception in diabetic women. [La contraception chez la femme diabétique.]
  140. Contraception in teenagers.
  141. Contraception should be available to non-menstruating women.
  142. Contraceptive applications of estrogen.
  143. Contraceptive considerations for adolescents.
  144. Contraceptive considerations for older women.
  145. Contraceptive counseling in managed care: preventing unintended pregnancy in adults.
  146. Contraceptive coverage laws: eliminating gender discrimination or infringing on religious liberties?
  147. Contraceptive efficacy.
  148. Contraceptive methods and risk factors of cardiovascular diseases in Tehranian women: Tehran Lipid and Glucose Study.
  149. Contraceptive morbidity and quality of care in Maharashtra.
  150. Contraceptive practice in a teaching hospital in south-east Nigeria.
  151. Contraceptive prevalence and fertility patterns in Nepal.
  152. Contraceptive sterilization and women's work careers.
  153. Contraceptive sterilization: global issues and trends.
  154. Contraceptive steroids influence the hemostatic activation state in healthy men.
  155. Contraceptive use among school age adolescents in Edo State, Nigeria.
  156. Contraceptive use behavior among never married young women who are seeking pregnancy termination in Beijing.
  157. Contraceptive use dynamics: a comparative study of Tamil Nadu and Uttar Pradesh.
  158. Contribution of family planning programme to fertility decline in Botswana.
  159. Correcting the record. Sacred Choices: the Right to Contraception and Abortion in Ten World Religions, [by] Daniel c. Maguire. Book review.
  160. Counseling about injectable progesterone contraceptives: how to correct the myths? [Counseling des contraceptifs progestatifs injectables : comment corriger les rumeurs ?]
  161. Counseling and combined estrogen-progestin oral contraception: how to correct the myths? [Counseling et contraception orale oestro-progestative combinée: comment corriger les rumeurs?]
  162. Counselling and communicating with men to promote family planning in Kenya and Zimbabwe: findings, lessons learned, and programme suggestions.
  163. Current perspectives on emergency contraception.
  164. A demographic profile of the people of Jammu and Kashmir. 5. Family planning.
  165. Determinants of unmet need for contraception in Uttar Pradesh.
  166. Developing countries face the challenge of a growing need for contraceptives. [Les pays en developpement face au defi du besoin croissant de contraceptifs.]
  167. Differences between emergency contraception users in the United States and the United Kingdom.
  168. Differentials in contraceptive mix: a state level study.
  169. The difficulties of intrauterine contraceptive research [editorial]
  170. Dismantling India's contraceptive target system: an overview and three case studies.
  171. The economics of family planning and underage conceptions.
  172. Education for contraceptive use by women after childbirth.
  173. Effort measures for family planning action programs: past trends and future prospects.
  174. Efforts renew to deny family planning funds to agencies that offer abortions.
  175. Emergency contraception : America's best kept secret. [Contraception d'urgence : le secret le mieux gardé d'Amérique.]
  176. Emergency contraception and the global gag rule: an unofficial guide.
  177. Emergency contraception provision: a survey of emergency department practitioners.
  178. Emergency contraception reclassified as contraception in Ireland.
  179. Emergency contraception.
  180. Emergency contraception.
  181. Emergency contraception. [La contraception d'urgence.]
  182. Emergency contraception: a study among family planning providers and women in three districts of Uttar Pradesh, India.
  183. Emergency contraception: the need to increase public awareness.
  184. Employee benefits. Contraception coverage at America's catholic universities.
  185. Empowering frontline staff to improve the quality of family planning services: a case study in Tanzania.
  186. Establishing reliability and validity of an instrument measuring Jordanian Muslim women's contraceptive beliefs.
  187. Ethical guidelines regarding privacy and confidentiality in reproductive medicine. Testing for genetic predisposition to adult onset disease. Guidelines in emergency contraception. FIGO committee report.
  188. Evaluation of a mass media campaign on contraception in France.
  189. Evaluation of family planning programmes in Nepal using index of contraception.
  190. Evaluation of menstrual and haematological parameters, after 36 months of Norplant contraception.
  191. Every child a wanted child: mid-life women's experiences of contraception.
  192. Expanding choices: the need for contraceptive and STD prevention research and development.
  193. Extended cycling of oral contraceptive pills for adolescents.
  194. Fact sheet on emergency contraception.
  195. Family influences on adolescent sexual and contraceptive behavior.
  196. Family planning alone viewed as insufficient.
  197. Family planning and reproductive health in China.
  198. Family planning and rural development. [Planification familiale et développement rural.]
  199. Family planning can reduce high infant mortality levels.
  200. Family planning choices of young couples attending antenatal clinics in Delhi: an analysis of husbands' and wives' views.
  201. Family planning in Bangladesh [letter]
  202. Family planning in Bangladesh.
  203. Family planning in refugee settings.
  204. Family planning law and China's birth control situation. Interview [with Zhao Bingli]
  205. Family planning programme in Nepal: achievement and constraints.
  206. Family planning promotion, contraceptive use and fertility decline in Ghana.
  207. A family planning success story. [Un exemple à suivre en matière de planning familial.]
  208. Family planning worldwide 2002 data sheet. Data and estimates of contraceptive use and related reproductive health indicators for the countries and regions of the world. [Wallchart]
  209. Fertility and family planning in rural Tibet.
  210. Fertility behaviour and knowledge, perception and current use of modern contraceptive among adolescent girls: a study of Padmakanya Multiple Campus, Bagbazar, Kathmandu.
  211. First contraceptive patch offers once-a-week dosing. FDA approves Ortho Evra transdermal contraceptive.
  212. First contraceptive skin patch.
  213. First method of family planning: a neglected information by health planners and service providers in Nepal.
  214. In France, contraception is more and more medicalized, but induced abortion is not on the decline. [En France, la contraception est de plus en plus medicalisee, mais l'IVG ne recule pas.]
  215. The Global Partners Initiative: building support for international family planning.
  216. High-risk teen compliance with prescription contraception: an analysis of Ohio Medicaid claims.
  217. HIV / STD risk and sexual strategies among women family planning clients in New York: Project FIO.
  218. Hormonal contraception: what is new? The ESHRE Capri Workshop Group.
  219. How a family planning association turned its approach to sexual health on its head: collaborating with communities in Belize.
  220. How Chinese parents view contraception for unmarried youth.
  221. How safe is emergency contraception? [Grado de seguridad de la anticoncepción de emergencia.]
  222. How to improve use of emergency contraception by adolescents? [Comment ameliorer l'utilisation de la contraception d'urgence par les adolescents?]
  223. Husband-wife communication about family planning in Bangladesh: evidence from the 1996-97 Bangladesh Demographic and Health Survey.
  224. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.
  225. Implantable contraceptives for women.
  226. Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: results of an observational clinical evaluation.
  227. Improving compliance in oral contraception: "the reminder card."
  228. Incorporating sexuality and couple issues in family planning training.
  229. Increasing contraception reduces abortion.
  230. Increasing options with natural family planning. [Ampliando opciones con la planificación familiar natural.]
  231. The influence of the service availability environment on contraception during the course of fertility transition.
  232. injectable contraception. [La contraception injectable.]
  233. Injectable contraceptives : a worldwide perspective [editorial] [Contraceptifs injectables : une perspective mondiale] [éditorial.]
  234. Integration of HIV / STI prevention, sexuality, and dual protection in family planning counseling: a training manual. Volume 1 - Manual. Working draft.
  235. Integration of STI/HIV/AIDS in family planning services: the FPAI experience.
  236. International family planning programs: criticisms and responses.

     

  237. Intra-vas deferens injection of styrene maleic anhydride gel for male contraception: Is it safe?
  238. Intrauterine and barrier contraception. A practical review of recent developments.
  239. Introducing new contraceptive methods from launch to delivery.
  240. The introduction of a transdermal hormonal contraceptive (Ortho Evra / Evra)
  241. Involvement of males in practice of contraception in Maharashtra.
  242. Iran's family planning program: responding to a nation's needs.
  243. Jordanian men's attitudes and views of birth-spacing and contraceptive use (a qualitative approach)
  244. Knowledge and attitudes about the differences between emergency contraception and medical abortion among middle-class women and men of reproductive age in Mexico City. [Los conocimientos y actitudes sobre las diferencias entre la anticoncepción de emergencia y el aborto médico entre las mujeres y los hombres de clase media de edad reproductiva en Ciudad de México.]
  245. Knowledge and use of emergency contraception in a tertiary referral unit in a developing country.
  246. LAM (lactational amenorrhea method): a modern postpartum contraceptive method for women who breastfeed. Training module for health and family planning service providers.
  247. Learning about clients' needs: family planning field workers in the Philippines.
  248. Long-term effects of oral contraceptives on ovarian cancer risk.
  249. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance.
  250. Low goitre prevalence among users of oral contraceptives in a population sample of 3712 women.
  251. Male birth-control pill studied.
  252. Male contraception.
  253. New metallic implant used for permanent contraception in women: evaluation of MR safety.
  254. New methods for 2002: the birth control patch.
  255. New methods for 2002: the vaginal contraceptive ring.
  256. A new, non-hormonal birth control method with dual action: the FemCap.
  257. Nonoxynol-9 spermicide contraception use -- United States, 1999.
  258. A note on family planning programme in Nepal.
  259. The occupational profile and associated training needs of the family planning nurse prescriber.
  260. Of interception, postcoital contraception and the morning after. Twenty five years ago: then and now.
  261. Offering a choice of contraceptive methods in Deqing county, China: changing practice in the family planning program since 1995.
  262. Operations research on ESP delivery in urban areas. Meeting additional health and family-planning needs of clients by addressing missed opportunities: an urban experience.
  263. Opinions of imams about family planning and their use of methods in Kayseri, Turkey.
  264. Oral contraception update: focus on a new progestin.
  265. Oral contraception: patterns of non-compliance. The Coraliance study.
  266. The oral contraceptive pill and the principle of double effect.
  267. Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4+ T cells in the cervical epithelium of healthy women.
  268. Oral contraceptives and central retinal vein occlusion [letter]
  269. Oral contraceptives and cervical cancer [letter]
  270. Oral contraceptives and cervical cancer [letter]
  271. Oral contraceptives and cervical cancer [letter]
  272. Oral contraceptives and cervical cancer. Author's reply [letter]
  273. Oral contraceptives and nutritional status in adolescent British girls.
  274. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
  275. Oral contraceptives, parity, and cervical cancer.
  276. Oral contraceptives: views among primary health-care physicians and the general population.
  277. The origins and evolution of family planning programs in developing countries.
  278. Ortho Evra -- a contraceptive patch.
  279. Ovès -- the new contraceptive cap.
  280. Ovès -- the new contraceptive cap. Fitting instructions.
  281. Ovès -- the new contraceptive cap. Published data.
  282. Parent-adolescent communication about sex and birth control: a conceptual framework.
  283. Perceptions of and attitudes towards male infertility in northern Botswana: some implications for family planning and AIDS prevention policies.
  284. A pharmacokinetic study with a low-dose oral contraceptive containing 20 micrograms ethinylestradiol plus 100 micrograms levonorgestrel.
  285. Philippines push for natural family planning.
  286. Pitfalls and possibilities: managing RTIs in family planning and general reproductive health services.
  287. Policy aspects of achieving contraceptive security.
  288. Population control: are contraceptives the only panacea? [editorial]
  289. Postpartum contraception. [Contraception du post-partum.]
  290. The power of the pill: oral contraceptives and women's career and marriage decisions.
  291. Preclinical evaluation of sodium cellulose sulfate (ushercell) as a contraceptive antimicrobial agent.
  292. Predictors of intention to promote family planning: a survey of Protestant seminarians in the United States.
  293. Prevalence and determinants of contraceptive practice in a defined Nigerian population.
  294. Prevalence of and risk indicators for STIs among women seeking induced abortions in two urban family planning clinics in Shandong province, People's Republic of China.
  295. Progestin contraceptives.
  296. Proposed new rule may impact family planning.
  297. Protecting fertility. Contraceptives pose no threat, but STIs do.
  298. Pure progestin contraception. [La contraception progestative pure.]
  299. Qualitative analysis of African-American adolescent females' beliefs about emergency contraceptive pills.
  300. A qualitative study on family planning in the Philippines -- findings among the industry workers sub-sample.
  301. A qualitative study on family planning in the Philippines.
  302. A randomized comparative study on mifepristone alone and in combination with tamoxifen for emergency contraception.
  303. Rape survivors deserve the standard of care: emergency contraception.
  304. Reasons for pregnancy termination, contraceptive habits and contraceptive failure among Swedish women requesting an early pregnancy termination.
  305. Repeat emergency contraception: facing our fears.
  306. Reply [to Dickey letter on side effects and oral contraceptive pill discontinuation rate in rural Bangladesh] [letter]
  307. Repositioning family planning in Africa: a call to action.
  308. Reproductive health / family planning campaign enters new phases in 2002.
  309. Reproductive health and family planning assistance to Turkey, 1990-2002. Successful strategies. [Assistance en matière de santé reproductive et de planning familial à la Turquie 1990-2002. Succès stratégiques.]
  310. Reproductive health including family planning. Background paper for the discussion of item 9 of the provisional agenda, Fifth Asian and Pacific Population Conference, Senior Officials Segment, 11-14 December 2002, Bangkok.
  311. Reproductive health, including family planning. (Item 9 of the provisional agenda), Fifth Asian and Pacific Population Conference, Senior Officials Segment, 11-14 December 2002, Bangkok.
  312. Reproductive, sexual and contraceptive behaviour of adolescents in Niger State, Nigeria. [Comportement contraceptif, sexuel et reproductif chez les adolescents de l'Etat du Niger, au Nigeria.]
  313. A research agenda for male contraception.
  314. Research eyes MI risk in oral contraceptive use.
  315. Responding to Cairo: Case studies of changing practice in reproductive health and family planning.
  316. Results from the 2001 population change and family planning survey.
  317. Return to fertility in nulliparous and parous women after removal of the GyneFix intrauterine contraceptive system.
  318. Risks and benefits of oral contraceptive pills.
  319. The role of men in fertility and family planning program in Tigray region.
  320. Safe use of contraception seldom requires medical exams.
  321. Safety and tolerability of the new contraceptive sponge Protectaid.
  322. Securing future supplies for family planning and HIV / AIDS prevention.
  323. Selected practice recommendations for contraceptive use.
  324. Sexual behaviour and contraceptive use in female migrant workers in China.
  325. Sexual risk, sexually transmitted infections, and contraceptive options: empowering women in Mexico with information and choice. [Riesgo sexual, infecciones de transmisión sexual y opciones de anticoncepción: empoderamiento de las mujeres en México mediante la información y las opciones.]
  326. Sexuality, contraceptive choice and AIDS awareness among Nigerian undergraduates. [Sexualité, choix contraceptif et prise de conscience du SIDA chez les étudiants nigérians du premier cycle universitaire.]
  327. Sponge versus diaphragm for contraception.
  328. St. John's Wort and oral contraceptives: reasons for concern?
  329. Staff awareness, acceptance and compliance with locally developed guidelines within a community family planning service.
  330. Standard Days Method: a modern, effective method of family planning.
  331. Strategies for increasing concurrent barrier use among women using oral contraceptives.
  332. Sweet's syndrome induced by oral contraceptive.
  333. Switching emergency contraception to over-the-counter status.
  334. Taking charge of your fertility. The definitive guide to natural birth control, pregnancy achievement and reproductive health. Revised ed.
  335. Thailand. Making the emergency contraceptive pill more acceptable to students.
  336. Third generation oral contraceptives and risk of venous thrombosis. [Tredjegenerations-p-piller og risikoen for venose tromboser.]
  337. Timing of emergency contraception [letter]
  338. Tips for clinicians. New developments in contraception.
  339. Title X: the nation's cornerstone federal family planning program.
  340. To the Editor: Side effects and oral contraceptive pill discontinuation rate in rural Bangladesh [letter]
  341. Tolerance and acceptability of Norplant contraceptive implants: experience of A. Le Dantec University Hospital in Dakar, Senegal. [Tolerance et acceptabilite des implants contraceptifs Norplant. Experience au CHU A. Le Dantec de Dakar (Senegal)]
  342. Training service providers on emergency contraception: lessons learned from an OR study.
  343. A transdermal delivery system examined: ethinyl estradiol and norelgestromin for contraception.
  344. Triphasic versus monophasic oral contraceptives for contraception.
  345. Turkish women's satisfaction with family planning services.
  346. Twenty states now require contraceptive insurance coverage.
  347. Undermining international family-planning programmes [editorial]
  348. UNFPA welcomes EU funds for RH and family planning programmes. European Union pledges 32 million euros for reproductive health in 22 countries.
  349. Unmet need for family planning services: a study of Doti district.
  350. Unmet needs in family planning and the contraceptive transition in Burkina Faso, Cameroon and Cote d'Ivoire. [Besoins non-satisfaits en planification familiale et transition contraceptive au Burkina Faso, au Cameroun et en Cote d'Ivoire.]
  351. Unresolved issues in contraceptive health policy.
  352. Up against it. The clergy's struggle with the Catholic hierarchy over legal contraception.
  353. The vaginal contraceptive ring -- efficacy, caution, and instructions. [L'anneau vaginal contraceptif - efficacité, précautions et mode d'emploi.]
  354. Vaginal discharge syndromic management in family planning programs: a review of the literature.
  355. Vatican attacks provision of emergency contraception to Afghan refugees.
  356. Voluntarism and informed choice in family planning: the case of Kabupaten Sampang, Madura.
  357. What do the midwives think about contraception? [Que pensent les sages-femmes de la contraception?]
  358. What do women want? Counselling in contraception.
  359. When I talk about sexuality, I use myself as an example: sexuality counseling and family planning in Colombia. ["Cuando hablo sobre sexualidad, me utilizo como ejemplo": asesoramiento sobre sexualidad y planificación familiar en Colombia.]
  360. When women hide contraceptive use. Advantages of clandestine use may outweigh disadvantages.
  361. Where is the condom? Contraceptive practice in a rural district of South Africa. [Où est le préservatif ? Pratique contraceptive dans un district rural d'Afrique du Sud.]
  362. Women status, contraceptive use and fertility preferences in an agricultural society in Uttar Pradesh.
  363. Strategies for detection of sexually transmitted infection among family planning clients in Jamaica.
  364. The impact of a regional family planning service promotion initiative in sub-Saharan Africa: evidence from Cameroon.
  365. Effects of sex preference on contraceptive use, abortion and fertility in Matlab, Bangladesh.
  366. What influences contraceptive use among young women in urban squatter settlements of Karachi, Pakistan?
  367. The family planning program effort index: 1999 cycle.
  368. Contraceptive dynamics in Guatemala: 1978-1998. [Dinámica de la anticoncepción en Guatemala: 1978-1998.]
  369. Consequences of the shift from domiciliary distribution to site-based family planning services in Bangladesh.
  370. Monitoring quality of care in family planning programs: a comparison of observations and client exit interviews.
  371. Why Nigerian adolescents seek abortion rather than contraception: evidence from focus-group discussions.
  372. Timing of first intercourse among Malian adolescents: implications for contraceptive use.
  373. Why do family planning providers restrict access to services? An examination in Ghana.
  374. Contraceptive use, intention to use and unmet need during the extended postpartum period.
  375. Kinship networks and contraceptive choice in Nang Rong, Thailand.
  376. Family planning clinic services in the United States: patterns and trends in the late 1990s.
  377. Characteristics of adolescents' sexual partners and their association with use of condoms and other contraceptive methods.
  378. Union status, marital history and female contraceptive sterilization in the United States.
  379. Contraceptive failure in the first two years of use: differences across socioeconomic subgroups.
  380. Provision of hormonal contraceptives without a mandatory pelvic examination: the First Stop demonstration project.
  381. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.
  382. Optimization of contraceptive dosage regimen of Centchroman.
  383. Oral contraception and ear disease: findings in a large cohort study.
  384. Oral contraceptive failures and body weight: findings in a large cohort study.
  385. Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study.
  386. Oral contraceptive use in perimenopause.
  387. Oral contraceptive use in relation to age at menopause in the DOM cohort.
  388. Coping with changing conditions: alternative strategies for the delivery of maternal and child health and family planning services in Dhaka, Bangladesh.
  389. Cost savings from emergency contraceptive pills in Canada.
  390. Curable sexually transmitted infections among the clientele of a family planning clinic in Istanbul, Turkey. [Infections sexuellement transmissibles curables chez la clientèle d'une clinique de planning familial à Istanbul, en Turquie.]
  391. Current perspectives on oral contraceptive use.
  392. Motivational antecedents to contraceptive method change following a pregnancy scare: a couple analysis.
  393. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol / 100 micrograms levonorgestrel and 20 micrograms ethinylestradiol / 500 micrograms norethisterone.
  394. Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants.
  395. New aspects of injectable contraception.
  396. Noncompliance among a group of women using a novel method of contraception.
  397. A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men.
  398. A novel oral contraceptive initiation method: assessment of bleeding patterns.
  399. Delayed first injection of a once-a-month injectable contraceptive containing 25 mg of medroxyprogesterone acetate and 5 mg of E2-cypionate: effects on ovarian function.
  400. Delayed first injection of the once-a-month injectable contraceptive containing 25 micrograms medroxyprogesterone acetate and 5 micrograms estradiol-cypionate: effects on cervical mucus.
  401. Disobedient distributors: street-level bureaucrats and would-be patrons in community-based family planning programs in rural Kenya.
  402. Do better family planning services reduce abortion in Bangladesh?
  403. Do we really know how to respond to an unexpected event during the fitting of an intra-uterine contraceptive device?
  404. Does sex preference affect contraceptive use in Bangladesh?
  405. A 4-year follow-up study of women with Norplant-2 contraceptive implants.
  406. Adolescent contraceptive non-use and covariation among risk behaviors.
  407. APC resistance and third-generation oral contraceptives. Acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease.
  408. Campaign exposure and interpersonal communication as factors in contraceptive use in Bolivia. [Exposición durante las campañas y comunicación interpersonal como factores en el uso de anticonceptivos en Bolivia.]
  409. Central retinal artery occlusion and oral contraceptives.
  410. Cervical neoplasia risk in women provided hormonal contraception without a Pap smear.
  411. Changes in contraceptive use in Bulgaria, 1995-2000.
  412. Changes in providers' views and practices about emergency contraception with education.
  413. Charcoal treatment and risk of escape ovulation in oral contraceptive users.
  414. A client-centered approach to family planning: the Davao project.
  415. Clinical breast and pelvic examination requirements for hormonal contraception. Current practice vs evidence.
  416. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women.
  417. Comparison of a novel norgestimate / ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
  418. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel.
  419. Continuous combined oral contraceptives: results of a randomized controlled trial.
  420. Contraception and men attending a genitourinary medicine clinic.
  421. Contraception for adolescents: social, clinical and service-delivery considerations. Special communication from the World Health Organization.
  422. Contraceptive choices in HIV infected and HIV at-risk adolescent females.
  423. Contraceptive dispensing and selection in school-based health centers.
  424. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women.
  425. Contraceptive practices in women with systemic lupus erythematosus and / or antiphospholipid syndrome: What advice should we be giving?

     

  426. Contraceptive use at the family planning clinic of the University of Nigeria Teaching Hospital, Enugu, Nigeria.
  427. Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene. [Determinación de la dosis en un anticonceptivo oral combinado de 21 días y dosis baja con contenido de gestodeno.]
  428. Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 micrograms ethinyl estradiol and 75 micrograms gestodene.
  429. Drug interactions between oral contraceptives and antibiotics.
  430. Dynamics of contraceptive use and breastfeeding during the post-partum period in Peru and Indonesia. [Dinámica del uso de anticonceptivos y de la lactancia materna durante el puerperio en Perú e Indonesia.]
  431. Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 micrograms of ethinyl estradiol on the human endometrium.
  432. The effect of low-dose combined oral contraceptive pills versus injectable contraceptive (Depot Provera) on liver function tests of women with compensated bilharzial liver fibrosis.
  433. Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers.
  434. Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse.
  435. The effectiveness of preabortion contraception counseling.
  436. Effects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins, and coagulation parameters.
  437. Effects of contraceptive use on bone biochemical markers in young women.
  438. Effects of race, cigarette smoking, and use of contraceptive medications on resting energy expenditure in young women.
  439. Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size.
  440. Effects of two oral contraceptives, containing 30 or 20 micrograms of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women. [Efectos de dos métodos anticonceptivos orales, con contenido de 30 o 20 microgramos de etinil estradiol en combinación con gestodeno, sobre la fibrinólisis y coagulación de la sangre en mujeres brasileñas.]
  441. Efficacy and safety of a transdermal contraceptive system.
  442. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol.
  443. Emergency contraception in South Africa: knowledge, attitudes, and use among public sector primary healthcare clients.
  444. Emergency contraception over-the-counter: the medical and legal imperatives.
  445. Emergency contraception with Multiload Cu-375 SL IUD: a multicenter clinical trial.
  446. Emergency contraception: randomized comparison of advance provision and information only.
  447. Emergency hormonal contraception: the community pharmacy perspective.
  448. The emerging use of the 20-microgram oral contraceptive.
  449. Ends versus means: the role of markets in expanding access to contraceptives. Review article.
  450. Evaluating and developing contraceptive services: the results of an audit of the North Lambeth Primary Care Commissioning Group.
  451. Evaluation of a media campaign to increase knowledge about emergency contraception.
  452. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. A randomized controlled trial.
  453. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women.
  454. Evaluation of plasma levels of renin-aldosterone and blood pressure in women over 35 years treated with new oral contraceptives.
  455. The evolution of the family planning programme and its role in influencing fertility change in Kenya.
  456. Factors related to self-efficacy for use of condoms and birth control among women at risk for HIV infection.
  457. Family planning provision in the Trent health region: is it accessible to school aged teenagers?
  458. Feasibility of administering mifepristone as a once a month contraceptive pill.
  459. Fitting contraceptive diaphragms: can laywomen provide quality training for doctors?
  460. Further analysis of the theoretical effectiveness of the TwoDay method of family planning.
  461. Gender factors affect fatty acids-induced insulin resistance in nonobese humans: effects of oral steroidal contraception.
  462. Gender relations: husband-wife fertility and family planning decisions in Kenya.
  463. Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study.
  464. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study.
  465. How do family planning workers' visits affect women's contraceptive behavior in Bangladesh?
  466. Husbands' and wives' reports of contraceptive use. [Usage du contraceptif selon des maris et des femmes; [Informe de esposos y esposas sobre uso de anticonceptivos.]
  467. Immediate postabortal contraception with the levonorgestrel intrauterine device, Norplant, and traditional methods.
  468. Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations.
  469. Implanon contraceptive implants: effects on carbohydrate metabolism.
  470. Implications for evaluating the impact of family planning programs with a reproductive health orientation. [Repercusiones para la evaluación del impacto de los programas de planificación familiar con orientación a la salud reproductiva.]
  471. Increased depot medroxyprogesterone acetate use increases family planning program pharmaceutical supply costs.
  472. Insertion of an intrauterine contraceptive device after induced or spontaneous abortion: a review of the evidence.
  473. An integrated assessment of patient compliance with a weekly contraceptive patch (ORTHO EVRA / EVRA)
  474. Integrated summary of contraceptive efficacy with the ORTHO EVRA / EVRA transdermal system.
  475. Integration of an essential services package (ESP) in child and reproductive health and family planning with a micro-credit program for poor women: experience from a pilot project in rural Bangladesh.
  476. Internet availability of contraceptives.
  477. Is breast-feeding a substitute for contraception in family planning?
  478. Is the intrauterine device appropriate contraception for HIV-1-infected women?
  479. Knowledge and practice of contraception in United Arab Emirates women.
  480. Knowledge of the risks and benefits associated with oral contraception in a university-aged sample of users and non-users.
  481. Knowledge, attitudes, and practices of family planning among currently married women in Jordan Badia.
  482. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants.
  483. Levonorgestrel-only emergency contraception: real-world tolerance and efficacy.
  484. Likelihood of conception with a single act of intercourse: providing benchmark rates for assessment of post-coital contraceptives.
  485. Long-term effectiveness of a peer-based intervention to promote condom and contraceptive use among HIV-positive and at-risk women.
  486. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial.
  487. Mifepristone as a late post-coital contraceptive.
  488. Mifepristone effective as a late post-coital contraceptive.
  489. Mifepristone eyed for emergency contraception. [On envisage d'utiliser la mifepristone pour la contraception d'urgence.]
  490. Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol.
  491. On the mechanisms of action of short-term levonorgestrel administration in emergency contraception.
  492. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 micrograms ethinyl estradiol and 75 micrograms gestodene and a 21-day regimen with 20 micrograms ethinyl estradiol and 150 micrograms desogestrel.
  493. Ovarian and endometrial function during hormonal contraception.
  494. Over-the-counter use of oral contraceptives in Kuwait.
  495. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density.
  496. Peri-abortion contraceptive care: can we reduce the incidence of repeat abortions?
  497. Politics, population, and family planning in Guatemala: Ch'orti' Maya experiences. [Política, población y planificación familiar en Guatemala: experiencias de los Ch'orti' Maya.]
  498. The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives.
  499. Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health. International Collaborative Post-Marking Surveillance.
  500. Post-marketing surveillance of Norplant contraceptive implants: II. Non-reproductive health. International Collaborative Post-Marketing Surveillance of Norplant.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.